First Trust Advisors LP grew its holdings in AptarGroup, Inc. (NYSE:ATR – Free Report) by 42.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 538,554 shares of the industrial products company’s stock after acquiring an additional 160,763 shares during the period. First Trust Advisors LP owned about 0.84% of AptarGroup worth $67,868,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. increased its stake in AptarGroup by 20.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the industrial products company’s stock valued at $66,000 after purchasing an additional 91 shares in the last quarter. Salomon & Ludwin LLC raised its holdings in shares of AptarGroup by 38.5% in the fourth quarter. Salomon & Ludwin LLC now owns 360 shares of the industrial products company’s stock worth $44,000 after buying an additional 100 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of AptarGroup by 2.8% during the third quarter. Coldstream Capital Management Inc. now owns 3,923 shares of the industrial products company’s stock worth $524,000 after buying an additional 105 shares during the period. Vident Advisory LLC lifted its stake in shares of AptarGroup by 5.1% during the second quarter. Vident Advisory LLC now owns 2,304 shares of the industrial products company’s stock worth $360,000 after buying an additional 112 shares during the period. Finally, IFP Advisors Inc grew its holdings in shares of AptarGroup by 47.0% during the fourth quarter. IFP Advisors Inc now owns 369 shares of the industrial products company’s stock valued at $45,000 after buying an additional 118 shares during the last quarter. Institutional investors own 88.52% of the company’s stock.
Wall Street Analysts Forecast Growth Several equities analysts recently issued reports on ATR shares. Zacks Research raised AptarGroup from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Raymond James Financial reaffirmed an “outperform” rating and set a $160.00 price target on shares of AptarGroup in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of AptarGroup in a research note on Wednesday, June 24th. Bank of America raised AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 price objective on the stock in a report on Tuesday, July 14th. Finally, Wells Fargo & Company raised their price objective on AptarGroup from $144.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.80.
Check Out Our Latest Stock Report on ATR
AptarGroup Price Performance NYSE:ATR opened at $132.29 on Friday. AptarGroup, Inc. has a 1-year low of $103.23 and a 1-year high of $163.09. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.66 and a quick ratio of 1.14. The company has a 50 day moving average price of $121.42 and a 200-day moving average price of $126.22. The firm has a market cap of $8.44 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 3.30 and a beta of 0.39.
AptarGroup (NYSE:ATR – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The industrial products company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.04. AptarGroup had a net margin of 9.98% and a return on equity of 13.98%. The business had revenue of $982.87 million during the quarter, compared to the consensus estimate of $955.95 million. During the same quarter in the prior year, the firm posted $1.20 earnings per share. The company’s revenue was up 10.8% compared to the same quarter last year. AptarGroup has set its Q2 2026 guidance at 1.320-1.400 EPS. Equities research analysts forecast that AptarGroup, Inc. will post 5.41 EPS for the current year.
AptarGroup Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 20th. Shareholders of record on Thursday, July 30th will be given a dividend of $0.48 per share. The ex-dividend date is Thursday, July 30th. This represents a $1.92 dividend on an annualized basis and a yield of 1.5%. AptarGroup’s dividend payout ratio is currently 32.88%.
Insider Buying and Selling In other news, insider Shiela Vinczeller sold 3,555 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $112.61, for a total value of $400,328.55. Following the completion of the sale, the insider directly owned 27,078 shares in the company, valued at $3,049,253.58. The trade was a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Irene Elizabeth Hudson sold 1,264 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $123.43, for a total value of $156,015.52. Following the transaction, the executive vice president directly owned 1,480 shares of the company’s stock, valued at approximately $182,676.40. The trade was a 46.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.73% of the company’s stock.
AptarGroup Company Profile (Free Report)
AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.
In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.
See Also Five stocks we like better than AptarGroup Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for AptarGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AptarGroup and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFirst Trust Advisors LP Has $74.19 Million Stock Position in First Trust Nasdaq Cybersecurity ETF $CIBR
Wall Street expects a year-over-year decline in earnings on higher revenues when AptarGroup (ATR - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis maker of consumer-product dispensing systems is expected to post quarterly earnings of $1.34 per share in its upcoming report, which represents a year-over-year change of -19.3%.
Revenues are expected to be $1 billion, up 3.9% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.47% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for AptarGroup?For AptarGroup, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.56%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that AptarGroup will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that AptarGroup would post earnings of $1.15 per share when it actually produced earnings of $1.19, delivering a surprise of +3.48%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
AptarGroup appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announces the first commercial launch of its innovative auto-loading, dosing dropper technology called NeoDropper Autoload. Aptar’s technology is featured on Dermalogica’s FutureCode Booster skincare product. Designed for prestige skincare and dermocosmetic brands, this next-generation dropper packaging is intended to address consumer needs around dosage control, convenience and clean usage by supporting precision dispensing and user experience.
“We are advancing dropper and dosing packaging innovation to address evolving market needs and shape the future of precision dispensing for forward-thinking skincare brands."
Share Aptar’s NeoDropper Autoload reinvents the dropper experience by combining a twist-and-push dispensing mechanism and auto-loading dropper cap which automatically loads the applicator with consistent dose after each use. The unique, short applicator design is intended to prevent breakage while improving hygiene and dosage control. The dip tube inside the bottle is designed to allow consumers to use the formula until the last drop and help minimize formula waste.
“We are advancing dropper and dosing packaging innovation to address evolving market needs and shape the future of precision dispensing for forward-thinking skincare brands,” said Xavier Joseph, Vice President, Global Marketing and Innovation, Aptar Beauty.
Clinical skincare brands continue to gain traction in the U.S. beauty market* due to consumers seeking clinically validated products. This is why beauty brands are increasingly turning to advanced dispensing technologies to preserve formulas, which are incorporating potent ingredients and actives that require protection and dosage accuracy.
NeoDropper Autoload intends to address this market shift through a next-generation dropper technology engineered to enhance formula integrity, hygiene and dispensing precision to minimize product loss.
Professional-grade skincare brand, Dermalogica, selected NeoDropper Autoload for the new FutureCode Booster serum, an advanced longevity treatment designed to reverse daily DNA-related damage and defend against visible skin aging.
According to Manuela DeForge, Packaging Engineer Manager at Dermalogica, “FutureCode Booster has been positively received by consumers, particularly for its dispensing performance, ease of use, and overall user experience. Feedback highlights the value of delivering a consistent dose in a controlled and hygienic manner, demonstrating how thoughtful packaging design can enhance both product performance and everyday usability.”
This launch marks the latest milestone in the longstanding collaboration between Dermalogica and Aptar, reflecting a shared ambition to promote product performance and consumer experience through packaging innovation. In 2022, Dermalogica became the first prestige skincare brand to feature Aptar’s fully recyclable mono-material polyethylene dispensing pump (when paired with a PE or PET bottle), called Future, thus advancing the product circularity of its cleansing range.
*Circana, U.S. Beauty Market Skincare, Q1 2026.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
This press release contains forward-looking statements, including with regard to the expected performance and benefits of Aptar’s NeoDropper Autoload technology, including formula protection, dispensing precision and consistency, hygienic use and consumer experience; anticipated market acceptance and related commercial opportunities for the technology and products incorporating it. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: whether the technology and products incorporating it perform as expected; demand for and market acceptance of new products and technologies; customer and consumer preferences; our ability to develop, commercialize, manufacture and protect our technologies and products; product performance, quality or supply chain matters; the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Chicago Partners Investment Group LLC acquired a new stake in AptarGroup, Inc. (NYSE:ATR – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,051 shares of the industrial products company’s stock, valued at approximately $505,000.
A number of other large investors have also added to or reduced their stakes in ATR. Nordea Investment Management AB acquired a new stake in AptarGroup in the fourth quarter valued at $7,314,000. Northwestern Mutual Wealth Management Co. lifted its holdings in AptarGroup by 30,035.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 136,211 shares of the industrial products company’s stock worth $15,220,000 after buying an additional 135,759 shares during the period. Intech Investment Management LLC grew its position in shares of AptarGroup by 696.8% in the 4th quarter. Intech Investment Management LLC now owns 100,020 shares of the industrial products company’s stock valued at $12,198,000 after buying an additional 87,467 shares during the last quarter. Aurora Investment Counsel bought a new stake in shares of AptarGroup in the 4th quarter valued at about $1,310,000. Finally, Victory Capital Management Inc. increased its stake in shares of AptarGroup by 4.0% in the fourth quarter. Victory Capital Management Inc. now owns 2,291,454 shares of the industrial products company’s stock valued at $279,466,000 after buying an additional 88,717 shares during the period. Institutional investors own 88.52% of the company’s stock.
Insider Buying and Selling In related news, insider Shiela Vinczeller sold 3,555 shares of AptarGroup stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $112.61, for a total transaction of $400,328.55. Following the transaction, the insider owned 27,078 shares of the company’s stock, valued at $3,049,253.58. The trade was a 11.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Irene Elizabeth Hudson sold 1,264 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $123.43, for a total transaction of $156,015.52. Following the completion of the sale, the executive vice president owned 1,480 shares of the company’s stock, valued at approximately $182,676.40. The trade was a 46.06% decrease in their position. The SEC filing for this sale provides additional information. 0.73% of the stock is owned by company insiders.
AptarGroup Price Performance AptarGroup stock opened at $132.29 on Friday. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of 22.65, a PEG ratio of 3.31 and a beta of 0.39. AptarGroup, Inc. has a 52-week low of $103.23 and a 52-week high of $164.28. The stock’s 50 day moving average price is $120.21 and its two-hundred day moving average price is $125.96. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.14 and a current ratio of 1.66.
AptarGroup (NYSE:ATR – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The industrial products company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.15 by $0.04. The company had revenue of $982.87 million during the quarter, compared to the consensus estimate of $955.95 million. AptarGroup had a net margin of 9.98% and a return on equity of 13.98%. The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.20 EPS. AptarGroup has set its Q2 2026 guidance at 1.320-1.400 EPS. On average, equities analysts predict that AptarGroup, Inc. will post 5.41 earnings per share for the current year.
AptarGroup Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 20th. Shareholders of record on Thursday, July 30th will be paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date is Thursday, July 30th. AptarGroup’s payout ratio is 32.88%.
Analysts Set New Price Targets A number of equities analysts have recently issued reports on ATR shares. Bank of America upgraded AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 price objective for the company in a research report on Tuesday, July 14th. Raymond James Financial reissued an “outperform” rating and set a $160.00 target price on shares of AptarGroup in a research report on Wednesday. Wells Fargo & Company raised their price target on shares of AptarGroup from $144.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Weiss Ratings restated a “hold (c)” rating on shares of AptarGroup in a research report on Wednesday, June 24th. Finally, Zacks Research raised shares of AptarGroup from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, AptarGroup presently has an average rating of “Moderate Buy” and a consensus price target of $170.80.
Check Out Our Latest Report on ATR
AptarGroup Profile (Free Report)
AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.
In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.
Read More Five stocks we like better than AptarGroup Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for AptarGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AptarGroup and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEChicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRX
NEXT HEADLINE »Chicago Partners Investment Group LLC Makes New Investment in Nordson Corporation $NDSN
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.
As previously announced, Aptar will hold a conference call on Friday, July 31, 2026, at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time on the Investors page of the website.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
This press release contains forward-looking statements, including with regard to the payment of the quarterly cash dividend. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AptarGroup (ATR - Free Report) . This company, which is in the Zacks Containers - Paper and Packaging industry, shows potential for another earnings beat.
When looking at the last two reports, this maker of consumer-product dispensing systems has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 2.14%, on average, in the last two quarters.
For the last reported quarter, AptarGroup came out with earnings of $1.19 per share versus the Zacks Consensus Estimate of $1.15 per share, representing a surprise of 3.48%. For the previous quarter, the company was expected to post earnings of $1.24 per share and it actually produced earnings of $1.25 per share, delivering a surprise of 0.81%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for AptarGroup. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
AptarGroup currently has an Earnings ESP of +0.74%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 30, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
-- ATR 1072 is the company's first precision cardiology program to enter the clinic --
-- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --
, /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome.
"PRKAG2 syndrome and other rare genetic cardiomyopathies represent a profound unmet need — these are progressive, life-altering and life-threatening diseases that often strike early, affect multiple members of the same family, and have no approved therapy to address their root cause," said Kathleen Gallagher, President and Chief Executive Officer, Atrium Therapeutics. "FDA clearance of our IND and the launch of the Corventis™ Phase 1/2 trial reinforce our team's ability to move with speed on behalf of patients with the goal of delivering potential disease-modifying treatments."
Corventis™ is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate safety and efficacy trends in cardiac structure and function.
Clinical site initiation activities are currently underway, and Atrium expects the first participant to be enrolled by the end of 2026. Initial trial data demonstrating proof of concept is anticipated in the second half of 2027.
About ATR 1072
ATR 1072, the company's lead product candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation, potentially leading to improved heart function.
About PRKAG2 Syndrome
PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in the heart, thickened heart muscles, electrical conduction problems, and arrhythmias. Based on current scientific literature estimates, there are at least 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.
About the Corventis™ Trial
Corventis™ is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function. Additional information about the trial is available at www.corventistrial.com.
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.
For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
Availability of Other Information About Atrium Therapeutics
Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission (SEC) filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding: the safety, efficacy, success, positioning and advancement of our clinical program for ATR 1072 for the treatment of PRKAG2 syndrome pursuant to our IND application, including the expected timing of initiation, enrollment, dosing, availability of data and completion of Corventis™, our Phase 1/2 clinical trial evaluating ATR 1072; the study design and conduct of Corventis™; the disease-modifying potential of ATR 1072 to treat PRKAG2 syndrome; the therapeutic potential of our RNA delivery platform; and statements regarding our strategy, pipeline, and future operations. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant, known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the potential for clinical trial results to differ from our preclinical studies; our ability to timely enroll a sufficient number of patients in our clinical trials, such as Corventis™; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified in Atrium's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 publicly filed by Atrium with the SEC and in other filings and furnishings made by Atrium with the SEC from time to time. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2025 Corporate Sustainability Report entitled Progress in Motion. The report highlights activities across Aptar’s global operations from January 1 through December 31, 2025, and summarizes certain milestones and progress measured across the company’s global sustainability strategy, which is focused on three key pillars:
“Aptar’s progress in 2025 reflects our belief that sustainability is integral to how we operate, innovate and create value."
ShareCare - operating with care for employees, communities and the environment by aiming to continuously improve our impact and seeking to reduce our footprint;Collaboration - innovating alongside customers, suppliers, industry coalitions and nonprofits to help enable progress toward their goals – as well as for better outcomes for people and our planet; andCircularity - aiming to help the industry advance system-scale change intended to benefit people today and for generations to come by addressing climate change and the waste crisis.“Aptar’s progress in 2025 reflects our belief that sustainability is integral to how we operate, innovate and create value. Across our business, we continued advancing efforts through Care, Collaboration and Circularity that support our employees and communities, strengthen partnerships, improve our operations and respond to evolving expectations from customers and stakeholders. I am proud of our employees around the world whose commitment and expertise continue to turn our sustainability priorities into meaningful progress,” said Stephan B. Tanda, Aptar President and CEO.
Aptar has made progress advancing key areas of its global sustainability strategy. Highlights from Aptar’s Sustainability Report include:
At year-end 2025, 98% of Aptar’s electricity was sourced from renewable sources. Following the power purchase agreements in Europe and North America for a more localized source of renewable energy dedicated to Aptar, the company continued to make progress towards its science-based targets.In the past year, Aptar completed a Corporate Sustainability Reporting Directive (CSRD) aligned double materiality assessment. This assessment is intended to help the company identify and prioritize the topics that matter in terms of the company’s impact on people and the planet, while also considering the financial risks and opportunities.Aptar continues to support employees and communities through safety, health and wellness programs, learning and development opportunities, donations and participation in local charitable events, including support for women’s economic empowerment and emergency campaigns through Aptar’s global signatory organization, CARE®.Innovation towards more sustainable products continues to drive our teams across the globe. Working to better understand the life cycle impacts of our products and innovate to deliver performance value through the value chain and product life cycle remains a global focus.“Sustainability at Aptar is about keeping progress in motion and advancing responsibly, even as expectations and challenges evolve. Through our sustainability strategy, we are working to strengthen our operations, support our people and communities, and partner across our value chain to drive meaningful change. We remain focused on making steady, measurable progress that reflects both our commitments and the realities of the systems we operate within,” said Beth Holland, Aptar’s Chief Sustainability Officer.
Aptar’s 2025 Corporate Sustainability Report was prepared in accordance with the Global Reporting Initiative (GRI) Standards and obtained reasonable assurance from ERM CVS for our Scope 1 & 2 GHG Emissions and energy metrics. We also obtained limited assurance from ERM CVS for certain waste, water, product sustainability, and health and safety metrics. The complete assurance report can be found on digitally on the website.
To minimize paper waste, Aptar encourages readers to view the 2025 Corporate Sustainability Report digitally on our website under the Sustainability Reporting Center.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at www.aptar.com.
This press release contains forward-looking statements, including statements regarding our sustainability strategy, initiatives, goals, targets, anticipated progress, expected benefits and impacts, climate-related efforts, renewable electricity efforts, science-based targets, circularity initiatives, product sustainability efforts, collaborations, and employee and community-related initiatives. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could,” which are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: supplier participation, performance, transparency and data availability and accuracy; availability, cost and performance of renewable energy, lower-carbon materials, recycled materials and other alternatives; customer, consumer and stakeholder preferences and expectations; product performance, quality, sustainability, circularity or supply chain matters; the regulatory environment, including laws, regulations, standards, methodologies and reporting requirements relating to climate, emissions, renewable electricity, sustainability, product sustainability, waste, water, health and safety matters, and related assurance; changes in or interpretations of sustainability frameworks, standards and targets, including science-based targets; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and subsequent filings. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Digital solution will be designed to help guide users through injection process April 08, 2026 17:00 ET | Source: Enable Injections, Inc.
CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable’s preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help strengthen engagement support before, during and after administration.
Through this partnership, Aptar Digital Health will deliver a companion digital solution for Enable Injections’ enFuse® system, designed to enhance the patient experience and support adherence. Key features of the solution will include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes and symptom tracking - helping to empower patients and caregivers with greater confidence and control over the treatment process.
Built on a flexible and scalable architecture, the companion solution will be deployed alongside the enFuse® system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. Designed to evolve across the drug development lifecycle, the solution will support use cases from clinical trials through commercialization, aligned with development and launch strategies.
Adherence data and patient reported outcomes will be captured remotely, securely stored and made available through analytics dashboards that generate actionable insights to support clinical development, launch readiness and real-world use. The modular, program-specific design will allow pharmaceutical partners to integrate digital components into their clinical or commercial programs based on their needs. By combining device-generated data with patient reported insights, the solution will help drive more informed decisions grounded in real-world usage.
“The enFuse® companion solution reflects our vision of a more connected treatment experience that supports patients beyond the moment of injection,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “Together with Aptar Digital Health, we aim to combine innovative drug delivery with digital support tools that can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patient’s journey.”
“We are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,” said Damien McKeon, SVP Strategic Partnerships, Aptar Digital Health. “Large-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.”
About Aptar Digital Health
Aptar Pharma's Digital Health division is part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at www.aptardigitalhealth.com and http://www.aptar.com.
About Enable Injections
Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse® on-body drug delivery system. An innovative wearable technology, the enFuse® system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting improved outcomes, and advancing healthcare system economics.
Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for the joint commercial launch of their therapies in combination with the enFuse® technology. For more information, visit www.enableinjections.com.
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the presentation of new preclinical data from two of its lead programs at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held April 17–22 in San Diego, California.
The data, presented across two poster sessions at the world’s premier cancer research forum, advance Rakovina’s AI-driven pipeline targeting DNA damage response (DDR) vulnerabilities in hard-to-treat solid tumors. Both programs leverage generative AI platforms to address longstanding limitations of existing cancer therapies, including poor central nervous system (CNS) penetrance and the toxicity burden of drug combination regimens.
Novel Brain-Penetrant Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy in PTEN-Deficient Cancers
The first poster, titled A Novel Brain-Penetrant Dual ATR-mTOR Inhibitor for PTEN-Deficient Cancers (Presentation #1743, DNA Damage and Repair 2 session, April 20), presented preclinical data from Rakovina’s program to develop first-in-class CNS-penetrating molecules that simultaneously inhibit ATR and mTOR, two key drivers of survival in PTEN-deficient cancer cells. The program was developed in collaboration with Variational AI (Vancouver, BC) using the Enki™ generative AI platform.
PTEN deficiency is found in up to 40% of gliomas and 63% of breast cancers, which frequently metastasize to the brain. Simultaneous inhibition of ATR and mTOR is a rational therapeutic strategy in PTEN-deficient tumors, as PTEN loss activates both ATR-dependent DNA damage signaling and mTOR-driven cell survival pathways. However, no approved therapy directly addresses this dual vulnerability with effective CNS penetrance.
Using the Enki™ latent diffusion model to simultaneously optimize potency, selectivity, CNS penetrance, and ADMET properties, Rakovina generated and synthesized a curated set of novel small-molecule dual ATR-mTOR inhibitor candidates. Key findings presented at AACR 2026 include:
Enzymatic potency: Candidate compounds demonstrated equal or greater inhibition of recombinant ATR and mTOR enzymes compared to reference compounds ceralasertib and tuvusertib.Selectivity: Candidates are equally or more selective against PIKK family enzymes than the reference compounds ceralasertib and tuvusertib.Cell viability inhibition: Candidates inhibit cell viability of D283 medulloblastoma cells equally or more than reference compounds. A prototype lead candidate inhibited cell viability of both PTEN wild-type and PTEN-deficient cancer cell lines.Metabolic stability: After 45 minutes of incubation with human liver microsomes, candidate compounds demonstrated strong metabolic stability.CNS penetrance: Pharmacokinetic profiling following intraperitoneal administration in mice confirmed varying but measurable levels of CNS penetrance across candidates, with brain-to-plasma ratios broadly consistent with Enki™ AI predictions.In vivo efficacy: In a subcutaneous LNCaP prostate tumor model, a prototype lead candidate significantly prolonged tumor doubling time compared to vehicle control, with equal potency to reference compound ceralasertib. Critically, the Rakovina candidate was better tolerated than ceralasertib, demonstrating less weight loss with daily dosing and no signs of hematological toxicity at terminal complete blood count analysis. Optimization of candidate inhibitors is ongoing.
Novel AI-Designed Lipid Nanoparticle Formulation of kt-3283 Successfully Characterized
The second poster, titled Development of a Lipid Nanoparticle Formulation of the Bifunctional PARP and HDAC Inhibitor Kt-3283 (Presentation #6373, Drug Delivery session, April 21), presented preclinical formulation data on pLNP/kt-3283, developed in collaboration with NanoPalm (Riyadh, Saudi Arabia) using the EnsaliX AI platform.
kt-3283 integrates PARP inhibition and HDAC-mediated chromatin remodeling into a single compound, thereby improving the PARP efficacy, and eliminating the need for combination drug regimens and their associated toxicity risks. While kt-3283 has demonstrated potent anti-tumor activity across multiple tumor types in prior in vitro studies, its clinical viability has been limited by bioavailability and metabolic stability challenges. The pLNP formulation has been specifically designed to address these limitations.
Data presented confirm the successful assembly of the EnsaliX-designed patterned lipid nanoparticles. Physicochemical characterization confirmed uniform particle size, stable colloidal behavior, and a structured surface texture predicted to enhance cellular uptake. The pLNP/kt-3283 formulation demonstrated structure and particle size consistency supporting further biological evaluation.
Next steps include in vitro and in vivo characterization to confirm activity against PARP and HDAC enzymes, determine ADME properties, and evaluate efficacy in tumor models.
“Presenting at AACR is a meaningful milestone for our team, and these results represent a genuine step forward for both programs,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “The in vivo efficacy data for our ATR-mTOR inhibitor are particularly encouraging. The compound demonstrated potency comparable to an established reference compound while exhibiting a meaningfully improved tolerability profile. That is exactly the differentiation we are building toward. Combined with the initial characterization of our LNP formulation for kt-3283, we believe these results reinforce the potential of our AI-driven pipeline and support a path toward IND-enabling studies.”
Rakovina’s AI-powered discovery approach leverages generative AI platforms to evaluate billions of potential drug candidates at a pace not achievable through traditional methods. These capabilities are supported by the company’s access to the University of British Columbia’s lab infrastructure, enabling rapid in-house testing of lead compounds.
“These results demonstrate that our strategy of integrating AI-guided design with biological validation, is working as intended,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “For the ATR-mTOR program, our candidate inhibitors are tracking closely with the AI predictions for potency, selectivity, and CNS penetrance and our in vivo results give confidence in the direction of this program. For kt-3283, we have demonstrated that the EnsaliX-designed LNP formulation produces a well-characterized nanoparticle. The structured surface and organized phospholipid assembly we observed are precisely the properties expected to enhance nanoparticle stability and cellular uptake of kt-3283. Both programs have clear next steps, and we are moving forward with purpose.”
The data presented at AACR 2026 reinforce the progress of Rakovina’s AI-enabled DDR inhibitor pipeline and inform the next phase of preclinical development for both programs. For the ATR-mTOR program, further optimization of candidate inhibitors is ongoing. For the kt-3283 LNP program, the company will advance in vitro and in vivo studies to further characterize biological activity prior to evaluating efficacy in tumor models.
Rakovina intends to use these findings to advance best-in-class lead candidates toward IND-enabling studies in collaboration with pharmaceutical partners.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at
http://www.rakovinatherapeutics.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.
For Further Information Contact:
Investor Relations
Rakovina Therapeutics Inc. [email protected]
Wall Street expects a year-over-year decline in earnings on higher revenues when AptarGroup (ATR - Free Report) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis maker of consumer-product dispensing systems is expected to post quarterly earnings of $1.15 per share in its upcoming report, which represents a year-over-year change of -4.2%.
Revenues are expected to be $964.39 million, up 8.7% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.96% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for AptarGroup?For AptarGroup, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.09%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that AptarGroup will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that AptarGroup would post earnings of $1.24 per share when it actually produced earnings of $1.25, delivering a surprise of +0.81%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
AptarGroup doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Containers - Paper and Packaging industry, Avery Dennison (AVY - Free Report) , is soon expected to post earnings of $2.41 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +4.8%. Revenues for the quarter are expected to be $2.27 billion, up 5.7% from the year-ago quarter.
The consensus EPS estimate for Avery Dennison has been revised 0.2% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.16%.
When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Avery Dennison will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026.
As previously announced, Aptar will hold a conference call on Friday, May 1, 2026, at 8:00 a.m. Central Time to discuss the Company’s first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time on the Investors page of the website.
About Aptar
Aptar is a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
This press release contains forward-looking statements, including with regard to the payment of the quarterly cash dividend. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Cwm LLC increased its position in shares of AptarGroup, Inc. (NYSE:ATR – Free Report) by 102.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,781 shares of the industrial products company’s stock after purchasing an additional 5,457 shares during the quarter. Cwm LLC’s holdings in AptarGroup were worth $1,315,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Azzad Asset Management Inc. ADV bought a new position in shares of AptarGroup in the third quarter valued at approximately $1,383,000. Nordea Investment Management AB bought a new stake in AptarGroup during the fourth quarter worth $7,314,000. First Trust Advisors LP boosted its position in AptarGroup by 218.1% in the third quarter. First Trust Advisors LP now owns 372,369 shares of the industrial products company’s stock worth $49,771,000 after purchasing an additional 255,291 shares during the last quarter. Aptus Capital Advisors LLC boosted its position in AptarGroup by 14.1% in the third quarter. Aptus Capital Advisors LLC now owns 63,238 shares of the industrial products company’s stock worth $8,452,000 after purchasing an additional 7,829 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in AptarGroup by 390.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 10,276 shares of the industrial products company’s stock valued at $1,253,000 after purchasing an additional 8,179 shares during the period. Hedge funds and other institutional investors own 88.52% of the company’s stock.
Insiders Place Their Bets In other news, insider Gael Touya sold 3,500 shares of AptarGroup stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $141.35, for a total value of $494,725.00. Following the completion of the transaction, the insider owned 27,963 shares in the company, valued at $3,952,570.05. This trade represents a 11.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.73% of the stock is owned by corporate insiders.
Analysts Set New Price Targets Several brokerages have recently issued reports on ATR. KeyCorp reaffirmed an “overweight” rating and set a $220.00 target price on shares of AptarGroup in a research report on Friday, January 9th. Wells Fargo & Company upgraded shares of AptarGroup from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $133.00 to $144.00 in a research report on Friday, March 20th. Weiss Ratings restated a “hold (c)” rating on shares of AptarGroup in a report on Friday, March 27th. Finally, Robert W. Baird set a $156.00 price objective on shares of AptarGroup in a research report on Monday, February 9th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, AptarGroup presently has a consensus rating of “Hold” and an average price target of $173.00.
Check Out Our Latest Report on AptarGroup
AptarGroup Stock Performance NYSE:ATR opened at $124.10 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.62 and a quick ratio of 1.16. The business has a fifty day simple moving average of $131.64 and a two-hundred day simple moving average of $126.79. AptarGroup, Inc. has a 1 year low of $103.23 and a 1 year high of $164.28. The company has a market capitalization of $7.91 billion, a P/E ratio of 21.07, a P/E/G ratio of 2.96 and a beta of 0.49.
AptarGroup (NYSE:ATR – Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The industrial products company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.01. The firm had revenue of $962.74 million for the quarter, compared to analysts’ expectations of $878.58 million. AptarGroup had a return on equity of 14.25% and a net margin of 10.40%.The business’s revenue for the quarter was up 13.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.52 EPS. AptarGroup has set its Q1 2026 guidance at 1.130-1.210 EPS. On average, analysts expect that AptarGroup, Inc. will post 5.38 earnings per share for the current year.
AptarGroup declared that its board has authorized a share repurchase plan on Thursday, February 5th that allows the company to repurchase $600.00 million in shares. This repurchase authorization allows the industrial products company to purchase up to 7.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.
AptarGroup Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 6th will be given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date is Wednesday, May 6th. AptarGroup’s dividend payout ratio (DPR) is currently 32.60%.
AptarGroup Company Profile (Free Report)
AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.
In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.
See Also Five stocks we like better than AptarGroup Want to see what other hedge funds are holding ATR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AptarGroup, Inc. (NYSE:ATR – Free Report).
Receive News & Ratings for AptarGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AptarGroup and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEChicago Partners Investment Group LLC Invests $1.18 Million in Sprott Junior Uranium Miners ETF $URNJ
NEXT HEADLINE »iShares Core MSCI Pacific ETF $IPAC Shares Sold by Cwm LLC
The market expects Graphic Packaging (GPK - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 5. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis packaging company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of -88.2%.
Revenues are expected to be $2.07 billion, down 2.5% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 4.86% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Graphic Packaging?For Graphic Packaging, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -5.20%.
On the other hand, the stock currently carries a Zacks Rank of #5.
So, this combination makes it difficult to conclusively predict that Graphic Packaging will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Graphic Packaging would post earnings of $0.34 per share when it actually produced earnings of $0.29, delivering a surprise of -14.71%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Graphic Packaging doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Containers - Paper and Packaging industry, AptarGroup (ATR - Free Report) , is soon expected to post earnings of $1.15 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -4.2%. Revenues for the quarter are expected to be $964.39 million, up 8.7% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for AptarGroup has been revised 3% down to the current level. Nevertheless, the company now has an Earnings ESP of -1.09%, reflecting a lower Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that AptarGroup will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year.
First Quarter 2026 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
Reported sales increased 11% and core sales were flat Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12 Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency Adjusted EBITDA margin was 19.2% compared to 20.7% in the prior year Returned $131 million to shareholders through share repurchases and dividends Gael Touya named Aptar’s next CEO effective September 1, 2026 “Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO.
First Quarter Results
For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period.
First Quarter Segment Sales Analysis
(Change Over Prior Year)
Pharma
Beauty
Closures
Total AptarGroup
Reported Sales Growth
7%
19%
5%
11%
Currency Effects (1)
(7)%
(9)%
(5)%
(8)%
Acquisitions
(1)%
(7)%
0%
(3)%
Core Sales Growth
(1)%
3%
0%
0%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.
Pharma’s reported sales increased 7% when compared to the prior year period, with a currency contribution of 7%. Excluding acquisitions, core sales declined 1% in the quarter when compared to the prior year period. In the prescription division, sales for dispensing systems declined 10% primarily due to reduced sales in the emergency medicine category, as anticipated, while the pipeline for systemic nasal drug delivery continued to build. Consumer healthcare sales increased 4% on strong nasal decongestant and eye care solutions. Sales in the injectables division increased 20%, mainly driven by growth in demand for elastomeric components used for GLP-1, biologics and antithrombotics. Active material science solutions declined 1% due primarily to lower sales for diabetes test strips and probiotics. Adjusted EBITDA margin was 33.3%, a decrease of 150 basis points, reflecting a less favorable product mix, while royalties continued to positively impact margins.
Beauty’s reported sales increased 19% when compared to the prior year period, driven by a 9% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 3%. There was increased demand for fragrance dispensing, as well as hair care and body care applications. Adjusted EBITDA margin was 11.1%, a decline of 100 basis points, due to less favorable product mix, primarily in North America and isolated operational disruptions at a supplier as reported last quarter.
Closures’ reported sales rose 5% from the prior year quarter and core sales were flat, with a 5% currency benefit. While product volumes were up, core sales results were negatively impacted by the pass through of lower resin pricing. Adjusted EBITDA margin was 13.1%, a decline of 270 basis points, primarily due to the previously reported maintenance issues, temporary plant closures as a result of extreme weather in North America and certain investment write offs.
Reported first quarter earnings per share were $1.12 compared to $1.17 reported a year ago. Adjusted earnings per share were $1.19, compared to the prior year period’s adjusted earnings per share of $1.30, including comparable exchange rates. The first quarter reported effective tax rate was 22.4% and the adjusted effective tax rate was 22.6%, compared to the prior year period’s reported and adjusted effective tax rates of 25.8%.
Outlook
Regarding Aptar’s outlook, Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of the emergency medicine end market, our prescription division is expected to return to healthy growth, and we anticipate growth across a number of pharma end markets mainly due to strength in our injectables and consumer healthcare divisions. We also anticipate a strong quarter for Closures and continued growth in Beauty, particularly in fragrance. Heading into the quarter, we remain mindful of potential supply‑chain uncertainties as we continue to operate in a dynamic environment.”
Aptar currently expects adjusted earnings per share for the second quarter of 2026 to be in the range of $1.32 to $1.40. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.18 Euro to USD exchange rate.
Cash Dividends and Share Repurchases
As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. During the first quarter, Aptar repurchased 707 thousand shares for $100 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
Open Conference Call
There will be a conference call held on Friday, May 1, 2026 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.
About Aptar
Aptar is a global leader in drug delivery and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 14,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
Presentation of Non-GAAP Information
This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the quarter ended March 31, 2026, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.
This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Adjustments to reconcile net income to net cash provided by operations:
Depreciation
64,310
54,903
Amortization
11,415
10,744
Stock-based compensation
16,764
19,193
Provision for CECL
644
35
Loss (gain) on disposition of fixed assets
81
(271
)
Net loss on remeasurement of equity securities
1,086
1,096
Deferred income taxes
(4,567
)
(1,860
)
Defined benefit plan expense
3,443
3,277
Equity in results of affiliates
(714
)
(2,086
)
Impairment loss
901
—
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables
(33,030
)
(69,247
)
Inventories
(16,943
)
(6,043
)
Prepaid and other current assets
(12,393
)
(12,617
)
Accounts payable, accrued and other liabilities
36,422
33,324
Income taxes payable
103
(7,195
)
Retirement and deferred compensation plan
(15,271
)
(11,751
)
Other changes, net
(6,324
)
(7,423
)
Net Cash Provided by Operations
118,694
82,742
Cash Flows from Investing Activities:
Capital expenditures
(65,396
)
(56,862
)
Proceeds from sale of property, plant and equipment
1,327
79
Purchases of short-term investments, net
(103
)
(88
)
Acquisition of intangible assets, net
(592
)
(2,475
)
Notes receivable, net
(335
)
2,714
Net Cash Used by Investing Activities
(65,099
)
(56,632
)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts
2,930
79
Repayments of notes payable and overdrafts
(2,895
)
—
Proceeds and (repayments) of short term revolving credit facility, net
7,000
(23,880
)
Proceeds from long-term obligations
5,037
124
Repayments of long-term obligations
(127,927
)
(4,552
)
Payment of contingent consideration obligation
(2,197
)
—
Dividends paid
(30,920
)
(29,923
)
Proceeds from stock option exercises
18,516
3,375
Purchase of treasury stock
(99,973
)
(80,000
)
Redeemable noncontrolling interest
89
—
Net Cash Used by Financing Activities
(230,340
)
(134,777
)
Effect of Exchange Rate Changes on Cash
(3,150
)
10,662
Net Decrease in Cash and Equivalents and Restricted Cash
(179,895
)
(98,005
)
Cash and Equivalents and Restricted Cash at Beginning of Period
404,849
223,844
Cash and Equivalents and Restricted Cash at End of Period
$
224,954
$
125,839
AptarGroup, Inc.
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
($ In Thousands)
Three Months Ended
March 31, 2026
Consolidated
Pharma
Beauty
Closures
Corporate
& Other
Net Interest
Net Sales
$
982,868
$
438,560
$
363,635
$
180,673
$
—
$
—
Reported net income
$
72,767
Reported income taxes
21,004
Reported income before income taxes
93,771
106,658
14,458
9,184
(23,229
)
(13,300
)
Adjustments:
Restructuring initiatives
1,086
5
1,301
249
(469
)
Net investment loss
1,086
—
—
—
1,086
Transaction costs related to acquisitions
45
45
—
—
—
Purchase accounting adjustments related to acquisitions and investments
145
145
—
—
—
Other special items
3,727
3,727
—
—
—
Adjusted earnings before income taxes
99,860
110,580
15,759
9,433
(22,612
)
(13,300
)
Interest expense
16,942
16,942
Interest income
(3,642
)
(3,642
)
Adjusted earnings before net interest and taxes (Adjusted EBIT)
113,160
110,580
15,759
9,433
(22,612
)
—
Depreciation and amortization
75,725
35,643
24,723
14,224
1,135
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)
$
188,885
$
146,223
$
40,482
$
23,657
$
(21,477
)
$
—
Reported net income margins (Reported net income / Reported Net Sales)
7.4
%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)
19.2
%
33.3
%
11.1
%
13.1
%
Three Months Ended
March 31, 2025
Consolidated
Pharma
Beauty
Closures
Corporate
& Other
Net Interest
Net Sales
$
887,305
$
409,467
$
305,707
$
172,131
$
—
$
—
Reported net income
$
78,663
Reported income taxes
27,352
Reported income before income taxes
106,015
111,112
16,681
12,333
(25,574
)
(8,537
)
Adjustments:
Restructuring initiatives
2,042
190
395
1,352
105
Net investment loss
1,096
—
—
—
1,096
Adjusted earnings before income taxes
109,153
111,302
17,076
13,685
(24,373
)
(8,537
)
Interest expense
11,351
11,351
Interest income
(2,814
)
(2,814
)
Adjusted earnings before net interest and taxes (Adjusted EBIT)
117,690
111,302
17,076
13,685
(24,373
)
—
Depreciation and amortization
65,647
31,148
20,062
13,575
862
—
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)
$
183,337
$
142,450
$
37,138
$
27,260
$
(23,511
)
$
—
Reported net income margins (Reported net income / Reported Net Sales)
8.9
%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)
20.7
%
34.8
%
12.1
%
15.8
%
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ended
March 31,
2026
2025
Income before Income Taxes
$
93,771
$
106,015
Adjustments:
Restructuring initiatives
1,086
2,042
Net investment loss
1,086
1,096
Transaction costs related to acquisitions
45
—
Purchase accounting adjustments related to acquisitions and investments
145
—
Other special items
3,727
—
Foreign currency effects (1)
8,992
Adjusted Earnings before Income Taxes
$
99,860
$
118,145
Provision for Income Taxes
$
21,004
$
27,352
Adjustments:
Restructuring initiatives
279
506
Net investment loss
266
269
Transaction costs related to acquisitions
11
—
Purchase accounting adjustments related to acquisitions and investments
49
—
Other special items
953
—
Foreign currency effects (1)
2,320
Adjusted Provision for Income Taxes
$
22,562
$
30,447
Net (Income) Loss Attributable to Noncontrolling Interests
$
(4
)
$
135
Net Income Attributable to Redeemable Noncontrolling Interests
$
(89
)
$
—
Net Income Attributable to AptarGroup, Inc.
$
72,674
$
78,798
Adjustments:
Restructuring initiatives
807
1,536
Net investment loss
820
827
Transaction costs related to acquisitions
34
—
Purchase accounting adjustments related to acquisitions and investments
96
—
Other special items
2,774
—
Foreign currency effects (1)
6,672
Adjusted Net Income Attributable to AptarGroup, Inc.
$
77,205
$
87,833
Average Number of Diluted Shares Outstanding
64,834
67,491
Net Income Attributable to AptarGroup, Inc. Per Diluted Share
$
1.12
$
1.17
Adjustments:
Restructuring initiatives
0.01
0.02
Net investment loss
0.01
0.01
Transaction costs related to acquisitions
—
—
Purchase accounting adjustments related to acquisitions and investments
—
—
Other special items
0.05
—
Foreign currency effects (1)
0.10
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share
$
1.19
$
1.30
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.
AptarGroup, Inc.
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)
(In Thousands)
Three Months Ended
March 31,
2026
2025
Net Cash Provided by Operations
$
118,694
$
82,742
Capital Expenditures
(65,396
)
(56,862
)
Free Cash Flow
$
53,298
$
25,880
AptarGroup, Inc.
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)
(In Thousands, Except Per Share Data)
Three Months Ending
June 30,
Expected 2026
2025
Income before Income Taxes
$
139,714
Adjustments:
Restructuring initiatives
1,579
Net investment gain
(2,102
)
Transaction costs related to acquisitions
344
Foreign currency effects (1)
919
Adjusted Earnings before Income Taxes
$
140,454
Provision for Income Taxes
$
27,982
Adjustments:
Restructuring initiatives
421
Net investment gain
(515
)
Transaction costs related to acquisitions
86
Foreign currency effects (1)
184
Adjusted Provision for Income Taxes
$
28,158
Net Income Attributable to Noncontrolling Interests
$
(12
)
Net Income Attributable to AptarGroup, Inc.
$
111,720
Adjustments:
Restructuring initiatives
1,158
Net investment gain
(1,587
)
Transaction costs related to acquisitions
258
Foreign currency effects (1)
735
Adjusted Net Income Attributable to AptarGroup, Inc.
$
112,284
Average Number of Diluted Shares Outstanding
67,048
Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)
$
1.67
Adjustments:
Restructuring initiatives
0.02
Net investment gain
(0.03
)
Transaction costs related to acquisitions
—
Foreign currency effects (1)
0.01
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)
$1.32 - $1.40
$
1.67
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected adjusted earnings per share range for the second quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 22.5% to 24.5%. This tax rate range compares to our second quarter of 2025 effective tax rate of 20.0% on both reported and adjusted earnings per share. More News From AptarGroup, Inc.
AptarGroup (ATR - Free Report) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.2 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.25%. A quarter ago, it was expected that this maker of consumer-product dispensing systems would post earnings of $1.24 per share when it actually produced earnings of $1.25, delivering a surprise of +0.81%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AptarGroup, which belongs to the Zacks Containers - Paper and Packaging industry, posted revenues of $982.87 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.92%. This compares to year-ago revenues of $887.3 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
AptarGroup shares have added about 0.8% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for AptarGroup?While AptarGroup has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AptarGroup was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.31 on $999.46 million in revenues for the coming quarter and $5.38 on $3.94 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Containers - Paper and Packaging is currently in the bottom 19% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Karat Packing (KRT - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.
This company is expected to post quarterly earnings of $0.32 per share in its upcoming report, which represents a year-over-year change of -3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Karat Packing's revenues are expected to be $113 million, up 9.1% from the year-ago quarter.
On May 01, 2026, AptarGroup Inc ATR shares fell 3.8% to a current price of $119.02. The stock has experienced significant volatility over the past year, with a 52-week range between $103.23 and $164.28. The recent decline adds to its performance challenges, as the stock has lost 18.9% in the past year and is down 2.0% year-to-date.
GF Value™ verdict: The current price is $119.02, compared to a GF Value™ estimate of $152.14, indicating a 21.8% undervaluation.GF Score™: 91/100 (Strong), suggesting potential for higher long-term returns.Notable signal: Insider activity shows that insiders sold $0.8 million worth of shares in the last three months, indicating a lack of buying interest. Is ATR Overvalued or Undervalued? AptarGroup Inc ATR is currently trading below its GF Value™ estimate of $152.14, which suggests that the stock is undervalued by approximately 21.8%. This margin of safety may present a buying opportunity for investors seeking value; however, caution is warranted given the recent insider selling. The GF Valuation label indicates that the stock is considered modestly undervalued, which aligns well with its current price being significantly lower than its intrinsic value.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. While the undervaluation suggests potential upside, the lack of insider buying and the recent downward price trend may indicate underlying concerns that should be addressed before making any investment decisions.
How Does ATR's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 20.4x 31.1x (5-Year Median) Forward P/E 21.5x N/A AptarGroup's current P/E (TTM) of 20.4x is significantly below its 5-year median P/E of 31.1x, indicating that the stock is trading at a lower valuation compared to its historical averages. This P/E analysis supports the GF Value™ verdict of undervaluation, suggesting that ATR may be an appealing option for value-focused investors.
What Does ATR's GF Score™ Tell Us? The GF Score™ ranks stocks based on key aspects that help investors gauge their potential for superior returns. Here are the scores for AptarGroup Inc:
Metric Rating GF Score™ 91/100 Financial Strength 7/10 Profitability 8/10 Growth 9/10 Valuation 8/10 Momentum 5/10 The strong GF Score™ of 91/100 reflects robust prospects, particularly in growth (9/10) and profitability (8/10), indicating that the company has a solid financial foundation and growth trajectory. However, the momentum score of 5/10 suggests that the stock may currently be facing headwinds, reflected in its recent price declines. Hence, while the overall assessment is positive, investors may need to consider the mixed signals from momentum before making decisions.
What Are Insiders Doing with ATR Stock? In the past three months, insiders at AptarGroup have sold $0.8 million worth of shares, with no reported insider buying during this timeframe. This selling activity could suggest a lack of confidence from insiders regarding the company's short-term prospects or valuation. While insider selling does not automatically imply negative performance, it can indicate that those closest to the company may not expect significant short-term upside. Investors should take this into consideration alongside other valuation metrics and market conditions.
What This Means for Investors Based on the analysis, AptarGroup Inc ATR appears to be undervalued according to the GF Value™ assessment, which indicates a significant margin of safety. However, potential investors should weigh this against the recent insider selling and the stock's performance trends, as these factors could signal caution regarding immediate investment decisions.
For the complete analysis, visit the AptarGroup Inc ATR stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is ATR's GF Score™?
ATR's GF Score™ is 91/100, indicating strong potential for higher long-term returns based on its financial health, profitability, growth prospects, and valuation metrics.
Is ATR overvalued or undervalued?
ATR is considered undervalued, with a GF Value™ of $152.14 compared to its current price of $119.02, suggesting a potential upside of 21.8%.
What is ATR's P/E ratio?
ATR's P/E (TTM) ratio is 20.4x, which is significantly below its 5-year median of 31.1x, indicating that the stock is trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
PENSACOLA, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- Advanced Technology Recycling (ATR), a leading IT Asset Management and Electronics Refurbishment company, is pleased to announce that we are now offering wholesale electronics to the general public through our online auction site.
The newly rebuilt platform will offer bidding opportunities for personal and commercial buyers at all levels. Bidders will have access to millions of dollars' worth of refurbished electronics, including, but not limited to, computers, phones, servers, RAM, and other devices certified under the R2v3 Ready-for-Resale renewal process.
Buying through our new auction site gives customers direct access to ATR’s Renewed in America products: quality electronics renewed through trusted U.S. facilities that support responsible reuse and help keep valuable technology out of landfills. Every purchase helps advance sustainability while supporting American refurbishment, logistics, ecommerce, and technical jobs across ATR’s nationwide operations.
ATR also offers premium products through ATRStore.com, where customers can shop new-in-box items, Grade-A products, and a wide range of accessories at discounted rates. For buyers searching for hard-to-find items, specialty electronics, and collectibles, ATR also makes unique inventory and discounted electronics available through our three eBay stores. Together, these platforms give customers more ways to purchase virtually any electronic or technological device, in quantities that meet their individual needs, at discounted prices.
The R2 Ready for Resale renewal process ensures each product is carefully received, evaluated, tested, data-sanitized when applicable, and prepared for its next user through a responsible reuse channel. Items that meet resale standards are thoroughly tested, verified for functionality, and listed with clear condition details, giving customers confidence in exactly what they are purchasing. This process helps extend the useful life of quality electronics, so renewed products should absolutely be considered a smart, reliable, and sustainable purchase option.
“ATR’s auction site gives you a smarter way to save money on renewed products while creating U.S jobs, reducing electronic waste, and buying directly from a trusted source,” said Matthew Beer, eCommerce Manager for ATR
Getting started is simple and non-invasive: customers only need to register to bid, then can securely browse products, place bids, receive winning notifications, and initiate checkout processes through the site. We will not spam customers or abuse their contact information; account details are used to support a safe auction experience, purchase communication, billing, and secure order management. The platform is built around familiar auction and ecommerce features, including registered bidding, product photos and descriptions, private questions, winning notifications, billing entry, checkout, and supported payment processing.
“ATR makes it easy for new customers to sell equipment that does not require guaranteed destruction or line-by-line asset management reporting, offering a streamlined path for responsible recovery and resale. We welcome the opportunity to review what you have available, provide a competitive bid, and discuss practical equipment lifecycle solutions tailored to your needs. Interested parties looking to sell equipment to ATR can contact us at [email protected],” said Brodie Ehresman, Director of Marketing.
Visit ATRauctions.com today to start bidding on quality Renewed in America products that help you save money while supporting the reuse of sustainable technology. Organizations with surplus equipment can trust ATR for practical ITAD and Value Recovery solutions designed to maximize returns and extend the life of usable technology. To learn more, search Advanced Technology Recycling on Google and connect with a trusted leader in responsible electronics recovery.
About ATR
ATR is a certified woman-owned company and a nationally recognized leader in electronics recycling and IT asset management, proudly headquartered in Pensacola, FL. As an R2v3/RIOS certified company, ATR upholds the highest standards of environmental sustainability, data security, and responsible recycling. We are approved by the U.S. State Department for ITAR (International Traffic in Arms Regulations) disposal programs and offer GSA (General Services Administration) discounts to all federal agencies. With a deep commitment to providing comprehensive life cycle management services, ATR has built a reputation as an industry leader, delivering the most robust and trusted service portfolio in the market.
Key Takeaways AptarGroup beat Q1 earnings and sales estimates, but profit fell Y/Y and shares dipped 1%.ATR's Pharma unit faced destocking pressure, hurting prescription sales despite growth in injectables.AptarGroup saw margin compression from higher costs, weaker mix and operational disruptions. Shares of AptarGroup, Inc. (ATR - Free Report) have dipped 1% since posting first-quarter 2026 adjusted earnings of $1.19 per share on Thursday. Adjusted earnings declined 8% from $1.30 a year ago on a less favorable mix and pharma-related headwinds. However, the bottom line topped the Zacks Consensus Estimate of $1.15.
Quarterly sales rose 10.8% year over year to $983 million and beat the consensus mark of $964 million by 2%.
ATR’s Pharma Results Reflect Destocking HeadwindsPharma segment sales increased 7.1% year over year to $439 million. The reported figure missed our estimate of $454 million. The reported gain was aided by currency and a small acquisition contribution, while core sales slipped 1% on tougher comparisons in the prescription business.
Within Pharma, prescription core sales declined 10% as dispensing systems tied to emergency medicine were pressured by destocking. Offsetting this, consumer healthcare core sales increased 4% on nasal decongestant and eye-care solutions, while injectables delivered 20% core growth.
The Pharma segment posted adjusted EBITDA of $146 million compared with the prior-year quarter’s $142 million. We predicted adjusted EBITDA of $140 million for the segment.
AptarGroup’s Beauty Benefits From Fragrance DemandThe Beauty segment’s sales advanced 19% year over year to $364 million. The reported figure beat our estimate of $324 million. Core sales grew 3% as demand improved across fragrance dispensing and select personal care applications, with acquisitions and currency providing additional lift.
Profitability in Beauty was softer despite sales growth. Adjusted EBITDA came in at $40 million compared with the prior-year quarter’s $37 million. We predicted adjusted EBITDA of $34.5 million for the segment.
ATR’s Closures Sees Pricing Offset Volume GainsThe Closures segment’s sales increased 5% to $181 million. The reported figure beat our estimate of $177 million. While product volumes improved, core sales were flat because results were weighed down by the pass-through of lower resin pricing.
Margins were notably weaker in the segment. Adjusted EBITDA fell to $23.6 million compared with the prior-year quarter’s $27 million, driven by maintenance issues and temporary plant closures tied to extreme weather in North America, as well as certain investment write-offs. We predicted the segment’s adjusted EBITDA to be $28 million.
AptarGroup’s Profit Picture Shows Margin CompressionOn a reported basis, diluted earnings per share were $1.12 compared with $1.17 in the year-ago quarter. Operating income decreased to $107.5 million from $113.4 million as higher costs, and heavier depreciation and amortization weighed on results.
Adjusted EBITDA totaled $183 million compared with $189 million a year ago, translating to an adjusted EBITDA margin of 19.2%, down from the prior-year quarter’s 20.7%.
ATR’s Balance Sheet UpdatesAptarGroup ended the quarter with cash and equivalents of $222.5 million, down from $402 million at the end of 2025. Net cash provided by operating activities increased to $119 million from $83 million in the prior-year quarter.
Capital allocation remained shareholder-friendly. ATR repurchased 707 thousand shares for $100 million, returning $131 million to shareholders. The company’s consolidated leverage ratio stood at 1.43 at the quarter-end.
AptarGroup’s Q2 View Points to Broader-Based GrowthFor the second quarter of 2026, the company expects adjusted earnings per share of $1.32-$1.40.
Looking beyond the near term, AptarGroup expects 2026 capital investments of $260-$280 million, with most allocated to Pharma, and depreciation and amortization of $310-$320 million.
ATR Stock’s Price PerformanceThe company’s shares have lost 18.4% in the past year compared with the industry’s 8.7% decline.
Image Source: Zacks Investment Research
AptarGroup’s Zacks RankATR currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recent Performances of ATR’s PeersSonoco Products Company (SON - Free Report) delivered adjusted earnings of $1.20 per share in the first quarter of fiscal 2026, topping the Zacks Consensus Estimate of $1.19 by 0.84%. The figure declined 13% from $1.38 in the year-ago quarter.
Sonoco’s net sales were $1.68 billion, declining 1.9% year over year and lagging the Zacks Consensus Estimate of $1.71 billion by 1.95%. Pricing actions and productivity were key offsets to softer volume/mix during the quarter. SON’s top line dipped from the prior-year period primarily due to the absence of sales from the ThermoSafe temperature-assured packaging business, which was divested in November 2025.
Packaging Corporation of America (PKG - Free Report) posted adjusted earnings of $2.40 per share in the first quarter of 2026, up 3.9% from $2.31 a year ago. Packaging Corp’s results beat the Zacks Consensus Estimate of earnings $2.17 by 10.6%.
Net sales rose 10.6% year over year to $2.37 billion but missed the consensus mark of $2.41 billion by 1.9%. Favorable pricing and mix, along with lower fiber costs, supported Packaging Corp’s results, though special items weighed on reported profitability.
Avery Dennison Corporation (AVY - Free Report) registered adjusted earnings of $2.47 per share for the first quarter of 2026, rising 7.4% from the year-ago period and beating the Zacks Consensus Estimate of $2.41. Avery Dennison’s revenues were $2.298 billion, growing 7% year over year and surpassing the consensus mark of $2.271 billion by 1.2%.
Sales advanced 2.3%, excluding currency, as a 4.7% foreign-currency headwind weighed on reported growth. Organic sales increased 1.1%, while acquisitions were a 1.2% drag on the quarter’s growth bridge.
CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat
CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NYSE:KO
Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares
3 hours ago
Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock
3 hours ago
Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock
3 hours ago
Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it will present at two upcoming investor conferences:
Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 12:45 p.m. Eastern Standard Time. Wells Fargo Industrials and Materials Conference in Chicago, IL on Tuesday, June 9, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 1:45 p.m. Eastern Standard Time. A live audio webcast and presentation materials will be available in the "Investors" section of the Company's website at www.aptar.com.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, was named a CDP Supplier Engagement Leader, for the sixth consecutive year. This assessment, based on information reported within the 2025 CDP reporting cycle, highlights companies that are engaging their suppliers on climate change and supporting efforts to address emissions throughout the value chain.
By evaluating supplier engagement and recognizing best practices, CDP aims to accelerate global action on supply chain emissions and the transition towards a more sustainable economy. Aptar received an ‘A’ score on the Supplier Engagement Assessment (SEA), which is in the leadership band. As part of Aptar’s global sustainability strategy, the Company is working to cultivate a supply chain that is both socially inclusive and environmentally conscious, in support of customer and consumer needs.
In recent years, Aptar has continued to work with suppliers to support emission-reduction efforts aligned with its validated science-based targets and Carbon Transition Plan. More than 90% of Aptar’s total emissions are Scope 3 emissions, with over 80% of these linked to purchased goods and services, primarily raw materials such as plastics. For this reason, Aptar collaborates with suppliers, particularly those providing raw materials, to identify potential lower-carbon alternatives and advance circularity through product design and material selection.
Aptar’s Purchasing teams engage suppliers through both one-on-one collaboration and structured forums such as the Aptar Global Supplier Summit. The 2026 summit further strengthened collaboration through targeted challenge briefs, innovation exchanges, and dedicated working sessions that connected suppliers with Aptar teams to address operational and sustainability priorities. These interactions are designed to support alignment with Aptar’s sustainability strategy while advancing practical, supplier-led solutions. In parallel, Aptar continues to strengthen expectations for supplier performance and transparency. Aptar’s expectations of suppliers include sharing environmental data, participating in assessments and screening programs, and contributing to initiatives focused on materials, emissions reduction, and responsible sourcing.
The Supplier Engagement Assessment methodology provides a score which assesses supplier action as reported by a company’s CDP response. The score assesses the level of detail and comprehensiveness of the content, as well as the company’s awareness of climate change issues, management methods and progress towards action taken on climate change as reported in the response. The highest-rated companies are recognized as Supplier Engagement Leaders on the CDP website. For more information on Aptar’s sustainability progress, including its responsible supply chain efforts, visit aptar.com/sustainability.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.
This press release contains forward-looking statements, including statements regarding Aptar’s sustainability strategy, supplier engagement and collaboration, emissions-reduction efforts, science-based targets and Carbon Transition Plan, and related expectations regarding lower-carbon alternatives, circularity, supplier performance and transparency. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues,” “working,” “support,” “advance” and other similar expressions, or future or conditional verbs such as “will,” “should,” “would” and “could,” which are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: supplier participation, performance, transparency and data availability and accuracy; availability, cost and performance of lower-carbon materials, recycled materials and other alternatives; customer and consumer preferences; product performance, quality or supply chain matters; the regulatory environment, including laws, regulations, standards and reporting requirements relating to climate, emissions and sustainability matters; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
On June 09, 2026, AptarGroup Inc ATR shares rose 3.5% today, currently priced at $115.90. The stock has experienced a 52-week range of $103.23 to $164.28, reflecting notable price volatility over the past year.
GF Value™ verdict: Current price of $115.90 is 26.0% below the GF Value™ of $156.52, indicating a potential upside.GF Score™ of 82/100 suggests a strong overall performance relative to peers.Most notable signal: Insiders sold $1.0 million worth of shares in the past three months, showing no buying activity. Is ATR Overvalued or Undervalued? AptarGroup Inc's current trading price of $115.90 is significantly below the GF Value™ of $156.52, indicating that the stock is undervalued by approximately 26.0%. This gap presents a margin of safety for potential investors, as the stock is trading well below its intrinsic value as calculated by GuruFocus. The GF Valuation label of "Modestly Undervalued" supports the notion that there is an opportunity for price appreciation if the market corrects itself in favor of AptarGroup's fundamental value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation presents a favorable opportunity, it is important to consider the broader market conditions and the recent performance trends of the stock. Although AptarGroup's shares have seen a short-term uptick, its year-to-date performance remains at -4.2%, and the one-year decline is substantial at -22.4%. These factors suggest caution as the market assesses both potential recovery and inherent risks.
How Does ATR's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)19.9x30.9x Forward P/E21.0xN/A The current P/E (TTM) of 19.9x is significantly lower than its 5-year median of 30.9x, indicating that the stock is trading at a discount relative to its historical valuation. This analysis is consistent with the GF Value™ verdict, reinforcing the view that AptarGroup's shares are undervalued. The forward P/E of 21.0x also suggests that the market expects some improvement in earnings, although current valuations remain attractive relative to historical averages.
What Does ATR's GF Score™ Tell Us? MetricRating GF Score™82/100 Financial Strength6/10 Profitability8/10 Growth9/10 Valuation8/10 Momentum2/10 The GF Score™ of 82/100 indicates that AptarGroup Inc has a strong overall performance, with notable strengths in Growth (9/10) and Profitability (8/10). However, the Momentum score of 2/10 is a concern, as it reflects poor recent price performance, which may deter some investors. The Financial Strength rating of 6/10 suggests a stable but not overly robust financial position, warranting attention in terms of risk management and future growth potential.
What Are Insiders Doing with ATR Stock? In recent months, insider activity has reflected a bearish sentiment, with insiders selling $1.0 million worth of shares and no buying activity reported. This pattern may indicate a lack of confidence among management regarding the near-term prospects for the company. While insider selling does not inherently predict negative outcomes, it can be a signal for potential investors to exercise caution and consider the broader market context.
What This Means for Investors Based on the GF Value™ assessment, AptarGroup Inc appears to be undervalued at its current price of $115.90, presenting a potential opportunity for investors willing to look beyond recent price volatility and insider selling activity.
For the complete analysis, visit the AptarGroup Inc ATR stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is ATR's GF Score™?
ATR's GF Score™ is 82/100, indicating strong overall performance compared to peers and a favorable outlook for long-term returns.
Is ATR overvalued or undervalued?
ATR is currently undervalued, with a GF Value™ of $156.52 and a current price of $115.90, suggesting a 26.0% upside potential.
What is ATR's P/E ratio?
ATR's P/E (TTM) is 19.9x, which is significantly below its 5-year median of 30.9x, indicating that the stock is trading at a discount relative to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
